Citations

Clear

6274 citation(s) found for "To, Andrew".

133. ARGONAUT-III: Susceptibility of Carbapenem-resistant Klebsiellae to Cefepime-Taniborbactam
Bethel, Christopher R. , Marshall, Steven, Fowler, Vance G. , Papp‐Wallace, Krisztina M. , Mack, Andrew R , Patel, Robin , van Duin, David , Fowler, Vance G. , Rhoads, Daniel D. , Jacobs, Michael R. , Akker, Focco van den , Six, David A. , Moeck, Greg , Bonomo, Robert A.

Mayo Clinic

Open Forum Infectious Diseases | December 5, 2021 | Volume: 8 | Issue: Supplement_1 | Pages: S81-S82

10.1093/ofid/ofab466.133 Get It

Abstract Background Klebsiellae are Gram-negative pathogens responsible for serious nosocomial and community-acquired infections. Carbapenem resistance, both intrinsic and acquired, complicates therapy. Taniborbactam (formerly VNRX-5133; Fig 1) is a bicyclic boronate β-lactamase inhibitor (BLI) that inhibits all four Ambler classes of β-lactamase enzymes, both serine- and metallo-, with the notable exception of class B IMP β-lactamases. Taniborbactam is currently undergoing phase 3 clinical trials in combination with cefepime (FEP; Fig 1) as part of the β-lactam-BLI (BL-BLI) combination FEP-taniborbactam (FTB). Figure 1. Structures of taniborbactam and cefepime. The β-lactamase inhibitor is in red and the β-lactam antibiotic is in black. Methods We determined the activity of FTB against 200 carbapenem-resistant Klebsiellae (CRK) strains collected as part of the Antibiotic Resistance Leadership Group (ARLG) Consortium on Resistance against Carbapenems in Klebsiella (CRACKLE) study. Among these strains, 193 expressed class A KPCs, one expressed a class B NDM, and six expressed class D OXA-48 or variants. Broth microdilution minimum inhibitory concentrations (MIC)s were determined using the ThermoFisher Sensititre system with custom assay panels. American Type Culture Collection strains were used for quality control. The susceptible-dose-dependent breakpoint for FEP was provisionally used for FTB, where taniborbactam was fixed at 4 µg/mL. Results Among the 200 Klebsiella strains tested, susceptibility for β-lactams alone ranged from 1% for ceftazidime (CAZ), 2.5% for meropenem, and 13.5% for FEP (Table 1). The addition of BLIs increased % susceptibility compared to BL alone to: 98% for CAZ-avibactam (CZA); 95.5% for MEM-vaborbactam (MVB); and 99.0% for FTB. MIC50 and MIC90 were in the susceptible and provisionally susceptible range for CZA and MVB, and in the provisionally susceptible range for FTB. Analyzing the CZA and MVB non-susceptible strains, 7 of 9 MVB non-susceptible strains and 2 of 4 CZA-resistant strains were provisionally susceptible to FTB. Table 1. MIC50 and MIC90 values (μg/mL) and percent susceptibility for Klebsiella pneumoniae strains (n=200). AMK, amikacin; CST, colistin; CAZ, ceftazidime; CZA, ceftazidime-avibactam; FEP, cefepime; FTB, cefepime-taniborbactam; MEM, meropenem; MVB, meropenem-vaborbactam; TGC, tigecycline. * The breakpoint for CST is intermediate, as no susceptible breakpoint is available. ** The susceptible-dose-dependent breakpoint for FEP alone was provisionally applied to FTB, where taniborbactam was fixed at 4 μg/mL. Breakpoints from CLSI M100, 31st ed, 2021. Conclusion The addition of taniborbactam restored susceptibility to FEP in 99.0% of CRACKLE isolates studied, comparable to CZA and MVB. Taniborbactam also restored FEP activity against some MVB- and CZA-resistant strains. FTB may provide a promising therapy for CRK infections. Disclosures Robin Patel, MD, 1928 Diagnostics (Consultant)BioFire Diagnostics (Grant/Research Support)ContraFect Corporation (Grant/Research Support)Curetis (Consultant)Hylomorph AG (Grant/Research Support)IDSA (Other Financial or Material Support, Editor’s Stipend)Infectious Diseases Board Review Course (Other Financial or Material Support, Honoraria)Mammoth Biosciences (Consultant)NBME (Other Financial or Material Support, Honoraria)Netflix (Consultant)Next Gen Diagnostics (Consultant)PathoQuest (Consultant)PhAST (Consultant)Qvella (Consultant)Samsung (Other Financial or Material Support, Patent Royalties)Selux Diagnostics (Consultant)Shionogi & Co., Ltd. (Grant/Research Support)Specific Technologies (Consultant)TenNor Therapeutics Limited (Grant/Research Support)Torus Biosystems (Consultant)Up-to-Date (Other Financial or Material Support, Honoraria) Robin Patel, MD, BioFire (Individual(s) Involved: Self): Grant/Research Support; Contrafect (Individual(s) Involved: Self): Grant/Research Support; IDSA (Individual(s) Involved: Self): Editor’s stipend; NBME, Up-to-Date and the Infectious Diseases Board Review Course (Individual(s) Involved: Self): Honoraria; Netflix (Individual(s) Involved: Self): Consultant; TenNor Therapeutics Limited (Individual(s) Involved: Self): Grant/Research Support; to Curetis, Specific Technologies, Next Gen Diagnostics, PathoQuest, Selux Diagnostics, 1928 Diagnostics, PhAST, Torus Biosystems, Mammoth Biosciences and Qvella (Individual(s) Involved: Self): Consultant David van Duin, MD, PhD, Entasis (Advisor or Review Panel member)genentech (Advisor or Review Panel member)Karius (Advisor or Review Panel member)Merck (Grant/Research Support, Advisor or Review Panel member)Pfizer (Consultant, Advisor or Review Panel member)Qpex (Advisor or Review Panel member)Shionogi (Grant/Research Support, Scientific Research Study Investigator, Advisor or Review Panel member)Utility (Advisor or Review Panel member) Vance G. Fowler, Jr., MD, MHS, Achaogen (Consultant)Advanced Liquid Logics (Grant/Research Support)Affinergy (Consultant, Grant/Research Support)Affinium (Consultant)Akagera (Consultant)Allergan (Grant/Research Support)Amphliphi Biosciences (Consultant)Aridis (Consultant)Armata (Consultant)Basilea (Consultant, Grant/Research Support)Bayer (Consultant)C3J (Consultant)Cerexa (Consultant, Other Financial or Material Support, Educational fees)Contrafect (Consultant, Grant/Research Support)Debiopharm (Consultant, Other Financial or Material Support, Educational fees)Destiny (Consultant)Durata (Consultant, Other Financial or Material Support, educational fees)Genentech (Consultant, Grant/Research Support)Green Cross (Other Financial or Material Support, Educational fees)Integrated Biotherapeutics (Consultant)Janssen (Consultant, Grant/Research Support)Karius (Grant/Research Support)Locus (Grant/Research Support)Medical Biosurfaces (Grant/Research Support)Medicines Co. (Consultant)MedImmune (Consultant, Grant/Research Support)Merck (Grant/Research Support)NIH (Grant/Research Support)Novadigm (Consultant)Novartis (Consultant, Grant/Research Support)Pfizer (Grant/Research Support)Regeneron (Consultant, Grant/Research Support)sepsis diagnostics (Other Financial or Material Support, Pending patent for host gene expression signature diagnostic for sepsis.)Tetraphase (Consultant)Theravance (Consultant, Grant/Research Support, Other Financial or Material Support, Educational fees)Trius (Consultant)UpToDate (Other Financial or Material Support, Royalties)Valanbio (Consultant, Other Financial or Material Support, Stock options)xBiotech (Consultant) Daniel D. Rhoads, MD, Becton, Dickinson and Company (Grant/Research Support) Michael Jacobs, MBBS, Venatorx Pharmaceuticals, Inc. (Grant/Research Support) Focco van den Akker, PhD, Venatorx Pharmaceuticals, Inc. (Grant/Research Support) David A. Six, PhD, Venatorx Pharmaceuticals, Inc. (Employee) Greg Moeck, PhD, Venatorx Pharmaceuticals, Inc. (Employee) Krisztina M. Papp-Wallace, Ph.D., Merck & Co., Inc. (Grant/Research Support)Spero Therapeutics, Inc. (Grant/Research Support)Venatorx Pharmaceuticals, Inc. (Grant/Research Support)Wockhardt Ltd. (Other Financial or Material Support, Research Collaborator) Robert A. Bonomo, MD, entasis (Research Grant or Support)Merck (Grant/Research Support)NIH (Grant/Research Support)VA Merit Award (Grant/Research Support)VenatoRx (Grant/Research Support)
40. Lenzilumab Efficacy and Safety in Newly Hospitalized COVID-19 Subjects: Results From a Phase 3 Randomized Double-Blind Placebo-Controlled Trial
Temesgem, Zelalem, Polk, Christopher , Orenstein, Robert , Aronstein, William S., Durrant, Cameron, Chappell, Dale, Ahmed, Omar, Chappell, Gabrielle, Group, for the LIVE-AIR Study, Burger, Charles D. , Baker, Jason V. , Libertin, Claudia R. , Kelley, Colleen Frances , Marconi, Vincent C. , Catterson, Victoria M. , Ahmed, Omar, Badley, Andrew D. , Group, for the LIVE-AIR Study

Mayo Clinic

Open Forum Infectious Diseases | December 5, 2021 | Volume: 8 | Issue: Supplement_1 | Pages: S29-S29

10.1093/ofid/ofab466.040 Get It

Abstract Background Severe coronavirus disease 2019 (COVID-19) often results from the immune-mediated cytokine storm, triggered by granulocyte macrophage-colony stimulating factor (GM-CSF), potentially leading to respiratory failure and death. Lenzilumab, a novel anti-human GM-CSF monoclonal antibody, neutralizes GM-CSF and demonstrated potential to improve clinical outcomes in a matched case-cohort study of patients with severe COVID-19 pneumonia. This Phase 3 randomized, double-blind, placebo-controlled trial investigated the efficacy and safety of lenzilumab to improve the likelihood of survival without invasive mechanical ventilation (SWOV), beyond available treatments. Methods Hypoxic patients, hospitalized with COVID-19 (n=520), requiring supplemental oxygen, but not invasive mechanical ventilation, were randomized on Day 0 to receive lenzilumab (1800mg, n=261) or placebo (n=259), and available treatments, including remdesivir and/or corticosteroids; and were followed through Day 28. Results Baseline demographics were comparable between groups: male, 64.7%; mean age, 60.5 years; median CRP, 79.0 mg/L. Patients across both groups received steroids (93.7%), remdesivir (72.4%), or both (69.1%). Lenzilumab improved the primary endpoint, likelihood of SWOV in the mITT population, by 1.54-fold (HR: 1.54; 95%CI: 1.02-2.32, p=0.0403). Lenzilumab improved SWOV by 1.91-fold (nominal p=0.0073) and 1.92-fold (nominal p=0.0067) in patients receiving remdesivir or remdesivir and corticosteroids, respectively. A key secondary endpoint of incidence of IMV, ECMO or death was also improved in patients receiving remdesivir (p=0.020) or remdesivir and corticosteroids (p=0.0180). Treatment-emergent serious adverse events were similar across both groups. Conclusion Lenzilumab significantly improved SWOV in hypoxic COVID-19 patients upon hospitalization, with the greatest benefit observed in patients receiving treatment with remdesivir and corticosteroids. NCT04351152 Disclosures Zelalem Temesgem, MD, Humanigen, Inc (Grant/Research Support) Jason Baker, MD, Humanigen, Inc (Grant/Research Support) Christopher Polk, MD, Atea (Research Grant or Support)Gilead (Advisor or Review Panel member, Research Grant or Support)Humanigen (Research Grant or Support)Regeneron (Research Grant or Support) Claudia R. Libertin, MD, Gilead (Grant/Research Support) Colleen F. Kelley, MD, MPH, Gilead Sciences (Individual(s) Involved: Self): Grant/Research Support; Moderna (Individual(s) Involved: Self): Grant/Research Support; Novavax (Individual(s) Involved: Self): Grant/Research Support; Viiv (Individual(s) Involved: Self): Grant/Research Support Vincent Marconi, MD, Bayer (Consultant, Scientific Research Study Investigator)Eli Lilly (Consultant, Scientific Research Study Investigator)Gilead Sciences (Consultant, Scientific Research Study Investigator)ViiV (Consultant, Scientific Research Study Investigator) Victoria Catterson, PhD, Humanigen, Inc (Consultant) William Aronstein, MD, PhD, Humanigen, Inc (Consultant) Cameron Durrant, MD, Humanigen, Inc (Employee) Dale Chappell, MD, Humanigen, Inc (Employee) Omar Ahmed, PharmD, Humanigen, Inc (Employee) Gabrielle Chappell, MSc, Humanigen, Inc (Consultant) Andrew Badley, M.D., AbbVie (Consultant) for the LIVE-AIR Study Group, n/a, Humanigen, Inc (Grant/Research Support)
Socioeconomic and demographic factors in the diagnosis and treatment of Chiari malformation type I and syringomyelia
Akbari, Syed Hassan A., Rizvi, Asad A., CreveCoeur, Travis S., Han, Rowland H., Greenberg, Jacob K., Torner, James, Brockmeyer, Douglas L., Wellons, John C., Leonard, Jeffrey R., Mangano, Francesco T., Johnston, James M., Shah, Manish N., Iskandar, Bermans J., Ahmed, Raheel, Tuite, Gerald F., Kaufman, Bruce A., Daniels, David J., Jackson, Eric M., Grant, Gerald A., Powers, Alexander K., Couture, Daniel E., Adelson, P. David, Alden, Tord D., Aldana, Philipp R., Anderson, Richard C. E., Selden, Nathan R., Bierbrauer, Karin, Boydston, William, Chern, Joshua J., Whitehead, William E., Dauser, Robert C., Ellenbogen, Richard G., Ojemann, Jeffrey G., Fuchs, Herbert E., Guillaume, Daniel J., Hankinson, Todd C., O’Neill, Brent R., Iantosca, Mark, Oakes, W. Jerry, Keating, Robert F., Klimo, Paul, Muhlbauer, Michael S., McComb, J. Gordon, Menezes, Arnold H., Khan, Nickalus R., Niazi, Toba N., Ragheb, John, Shannon, Chevis N., Smith, Jodi L., Ackerman, Laurie L., Jea, Andrew H., Maher, Cormac O., Narayan, Prithvi, Albert, Gregory W., Stone, Scellig S. D., Baird, Lissa C., Gross, Naina L., Durham, Susan R., Greene, Stephanie, McKinstry, Robert C., Shimony, Joshua S., Strahle, Jennifer M., Smyth, Matthew D., Dacey, Ralph G., Park, Tae Sung, Limbrick, David D., Torner, James C. , Greene, Stephanie , Jackson, Eric M. , Stone, Scellig , Akbari, Syed Hassan A., Rizvi, Asad A., CreveCoeur, Travis S., Han, Rowland H., Greenberg, Jacob K., Brockmeyer, Douglas L., Wellons, John C., Leonard, Jeffrey R., Mangano, Francesco T., Johnston, James M., Shah, Manish N., Iskandar, Bermans J., Ahmed, Raheel, Tuite, Gerald F., Kaufman, Bruce A., Daniels, David J., Jackson, Eric M., Grant, Gerald A., Powers, Alexander K., Couture, Daniel E., Adelson, P. David, Alden, Tord D., Aldana, Philipp R., Anderson, Richard C. E., Selden, Nathan R., Bierbrauer, Karin, Boydston, William, Chern, Joshua J., Whitehead, William E., Dauser, Robert C., Ellenbogen, Richard G., Ojemann, Jeffrey G., Fuchs, Herbert E., Guillaume, Daniel J., Hankinson, Todd C., O’Neill, Brent R., Iantosca, Mark, Oakes, W. Jerry, Keating, Robert F., Klimo, Paul, Muhlbauer, Michael S., McComb, J. Gordon, Menezes, Arnold H., Khan, Nickalus R., Niazi, Toba N., Ragheb, John, Shannon, Chevis N., Smith, Jodi L., Ackerman, Laurie L., Jea, Andrew H., Maher, Cormac O., Narayan, Prithvi, Albert, Gregory W., Stone, Scellig S. D., Baird, Lissa C., Gross, Naina L., Durham, Susan R., Greene, Stephanie, McKinstry, Robert C., Shimony, Joshua S., Strahle, Jennifer M., Smyth, Matthew D., Dacey, Ralph G., Park, Tae Sung, Limbrick, David D.

Mayo Clinic

Journal of Neurosurgery: Pediatrics | December 3, 2021 | Volume: 29 | Issue: 3 | Pages: 288-297

10.3171/2021.9.peds2185 | PMID 34861643 Get It

OBJECTIVE The goal of this study was to assess the social determinants that influence access and outcomes for pediatric neurosurgical care for patients with Chiari malformation type I (CM-I) and syringomyelia (SM). METHODS The authors used retro- and prospective components of the Park-Reeves Syringomyelia Research Consortium database to identify pediatric patients with CM-I and SM who received surgical treatment and had at least 1 year of follow-up data. Race, ethnicity, and insurance status were used as comparators for preoperative, treatment, and postoperative characteristics and outcomes. RESULTS A total of 637 patients met inclusion criteria, and race or ethnicity data were available for 603 (94.7%) patients. A total of 463 (76.8%) were non-Hispanic White (NHW) and 140 (23.2%) were non-White. The non-White patients were older at diagnosis (p = 0.002) and were more likely to have an individualized education plan (p < 0.01). More non-White than NHW patients presented with cerebellar and cranial nerve deficits (i.e., gait ataxia [p = 0.028], nystagmus [p = 0.002], dysconjugate gaze [p = 0.03], hearing loss [p = 0.003], gait instability [p = 0.003], tremor [p = 0.021], or dysmetria [p < 0.001]). Non-White patients had higher rates of skull malformation (p = 0.004), platybasia (p = 0.002), and basilar invagination (p = 0.036). Non-White patients were more likely to be treated at low-volume centers than at high-volume centers (38.7% vs 15.2%; p < 0.01). Non-White patients were older at the time of surgery (p = 0.001) and had longer operative times (p < 0.001), higher estimated blood loss (p < 0.001), and a longer hospital stay (p = 0.04). There were no major group differences in terms of treatments performed or complications. The majority of subjects used private insurance (440, 71.5%), whereas 175 (28.5%) were using Medicaid or self-pay. Private insurance was used in 42.2% of non-White patients compared to 79.8% of NHW patients (p < 0.01). There were no major differences in presentation, treatment, or outcome between insurance groups. In multivariate modeling, non-White patients were more likely to present at an older age after controlling for sex and insurance status (p < 0.01). Non-White and male patients had a longer duration of symptoms before reaching diagnosis (p = 0.033 and 0.004, respectively). CONCLUSIONS Socioeconomic and demographic factors appear to influence the presentation and management of patients with CM-I and SM. Race is associated with age and timing of diagnosis as well as operating room time, estimated blood loss, and length of hospital stay. This exploration of socioeconomic and demographic barriers to care will be useful in understanding how to improve access to pediatric neurosurgical care for patients with CM-I and SM.
Ocular Sequelae in a Population-Based Cohort of Youth Diagnosed With Diabetes During a 50-Year Period
Bai, Patricia , Hodge, David O. , Mohney, Brian G., Barkmeier, Andrew J.

Mayo Clinic

JAMA Ophthalmology | December 2, 2021 | Volume: 140 | Issue: 1 | Pages: 51

10.1001/jamaophthalmol.2021.5052 | PMID 34854892 Get It

Nutrition, atherosclerosis, arterial imaging, cardiovascular risk stratification, and manifestations in COVID-19 framework: a narrative review
Munjral, Smiksha , Ahluwalia, Puneet , Saba, Luca , Singh, Inder M. , Chadha, Paramjit S., Turk, Monika, Johri, Amer M. , Khanna, Narendra N. , Višković, Klaudija , Laird, John R , Pareek, Gyan , Miner, Martin , Sobel, David , Balestrieri, Antonella , Sfikakis, Petros P. , Tsoulfas, George, Protogerou, Athanasios, Misra, Prasanna, Agarwal, Vikas , Teji, Jagjit S. , Al-Maini, Mustafa , Dhanjil, Surinder, Sockalingam, Meyypan, Saxena, Ajit Kumar , Rathore, Vijay , Fatemi, Mostafa , Viswanathan, Vijay , Krishnan, Pudukode, Omerzu, Tomaž , Naidu, Subbaram, Suri, Jasjit S. , Fatemi, Mostafa , Agarwal, Vikas , Munjral, Smiksha , Jamthikar, Ankush D. , Puvvula, Anudeep , Faa, Gavino , Mavrogeni, Sophie , Protogerou, Athanasios, Kitas, George D. , Kolluri, Raghu , Sharma, Aditya , Alizad, Azra , Krishnan, Pudukode R., Nicolaides, Andrew , Suri, Jasjit S.

Mayo Clinic

Frontiers in Bioscience-Landmark | December 1, 2021 | Volume: 26 | Issue: 11 | Pages: No page available

10.52586/5026 | PMID 34856770 Get It

Background: Atherosclerosis is the primary cause of the cardiovascular disease (CVD). Several risk factors lead to atherosclerosis, and altered nutrition is one among those. Nutrition has been ignored quite often in the process of CVD risk assessment. Altered nutrition along with carotid ultrasound imaging-driven atherosclerotic plaque features can help in understanding and banishing the problems associated with the late diagnosis of CVD. Artificial intelligence (AI) is another promisingly adopted technology for CVD risk assessment and management. Therefore, we hypothesize that the risk of atherosclerotic CVD can be accurately monitored using carotid ultrasound imaging, predicted using AI-based algorithms, and reduced with the help of proper nutrition. Layout: The review presents a pathophysiological link between nutrition and atherosclerosis by gaining a deep insight into the processes involved at each stage of plaque development. After targeting the causes and finding out results by low-cost, user-friendly, ultrasound-based arterial imaging, it is important to (i) stratify the risks and (ii) monitor them by measuring plaque burden and computing risk score as part of the preventive framework. Artificial intelligence (AI)-based strategies are used to provide efficient CVD risk assessments. Finally, the review presents the role of AI for CVD risk assessment during COVID-19. Conclusions: By studying the mechanism of low-density lipoprotein formation, saturated and trans fat, and other dietary components that lead to plaque formation, we demonstrate the use of CVD risk assessment due to nutrition and atherosclerosis disease formation during normal and COVID times. Further, nutrition if included, as a part of the associated risk factors can benefit from atherosclerotic disease progression and its management using AI-based CVD risk assessment.
Manifestations of Alzheimer’s Disease Genetic Risk in the Blood: A Cross-Sectional Multi-Omic Analysis in Healthy Adults Aged 18-90+
Earls, John C. , Lovejoy, Jennifer C., Funk, Cory C. , Kunkle, Brian W. , Martin, Eden R. , Ertekin‐Taner, Nilüfer , Golde, Todd E. , Hood, Leroy, Heath, Laura , Magis, Andrew T. , Kornilov, Sergey A. , Rappaport, Noa , Logsdon, Ben , Mangravite, Lara M. , Naj, Adam Christian , Price, Nathan D.

Mayo Clinic

No container title available | November 29, 2021 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.21203/rs.3.rs-1108842/v1 Get It

Abstract Background: Genetics play an important role in late-onset Alzheimer’s Disease (AD) etiology and dozens of genetic variants have been implicated in AD risk through large-scale GWAS meta-analyses. However, the precise mechanistic effects of most of these variants have yet to be determined. Deeply phenotyped cohort data can reveal physiological changes associated with genetic risk for AD across an age spectrum that may provide clues to the biology of the disease.Methods: We utilized over 2000 high-quality quantitative measurements obtained from blood of 2831 cognitively normal adult clients of a consumer-based scientific wellness company, each with CLIA-certified whole-genome sequencing data. Measurements included: clinical laboratory blood tests, targeted chip-based proteomics, and metabolomics. We performed a phenome-wide association study utilizing this diverse blood marker data and 25 known AD genetic variants, adjusting for sex, age, vendor (for clinical labs), and the first four genetic principal components; sex-SNP interactions were also assessed.Results: We observed statistically significant SNP-analyte associations for five genetic variants after correction for multiple testing (for SNPs in or near NYAP1, ABCA7, INPP5D, and APOE), with effects detectable from early adulthood. The ABCA7 SNP and the APOE2 and APOE4 encoding alleles were associated with lipid variability, as seen in previous studies; in addition, six novel proteins were associated with the e2 allele. The most statistically significant finding was between the NYAP1 variant and PILRA and PILRB protein levels, supporting previous functional genomic studies in the identification of a putative causal variant within the PILRA gene. Sex modified the effects of four genetic variants, with multiple interrelated immune-modulating effects associated with the PICALM variant. In post-hoc analysis, sex-stratified GWAS results from an independent AD case-control meta-analysis supported sex-specific disease effects of the PICALM variant, highlighting the importance of sex as a biological variable.Conclusions: Known AD genetic variation influenced lipid metabolism and immune response systems in a population of non-AD individuals, with associations observed from early adulthood onward. Further research is needed to determine whether and how these effects are implicated in early-stage biological pathways to AD. These analyses aim to complement ongoing work on the functional interpretation of AD-associated genetic variants.
Diagnostic value of aquaporin-4-IgG live cell based assay in neuromyelitis optica spectrum disorders
Redenbaugh, Vyanka , Montalvo, Mayra , Sechi, Elia , Fryer, James P., Lennon, Vanda A. , Mills, John R. , Wingerchuk, Dean M. , Chen, John J. , Bhatti, M. Tariq , López‐Chiriboga, A. Sebastian , Pittock, Sean J, Pittock, Sean J. , Lopez-Chiriboga, A Sebastian , Pittock, Sean J , Flanagan, E P , Pittock, S J , Chen, John J , Sechi, Elia , Redenbaugh, Vyanka , Buciuc, Marina , McKeon, Andrew , Weinshenker, Brian G. , Flanagan, Eoin P.

Mayo Clinic

Multiple Sclerosis Journal - Experimental, Translational and Clinical | November 26, 2021 | Volume: 7 | Issue: 4 | Pages: No page available

10.1177/20552173211052656 | PMID 34868626 Get It

Objective Determine the utility of aquaporin 4 IgG (AQP4-IgG) testing (live cell-based assay) for Neuromyelitis Optica Spectrum Disorders (NMOSD). Methods We included Mayo Clinic patients (1/1/2018-12/31/2019) tested for serum AQP4-IgG by live cell-based flow-cytometric assay. Medical records were reviewed to assess if patients fulfilled 2015 NMOSD criteria. Results Of 1371 patients tested, 41 were positive (3%) and all fulfilled NMOSD criteria with AQP4-IgG (specificity = 100%). Only 10/1330 testing negative met NMOSD criteria without AQP4-IgG (sensitivity = 80%) and seven of these 10 were MOG-IgG positive. Conclusions AQP4-IgG by live cell-based assay was highly specific and without false positives in a high throughput setting.
Autoimmune conditions in the World Trade Center general responder cohort: A nested case‐control and standardized incidence ratio analysis
Sacks, Henry S. , Smirnoff, Margaret, Carson, Deborah A. , Cooney, Michael L. , Shapiro, Moshe , Hahn, Christopher J., Dasaro, Christopher R. , Crowson, Cynthia S. , Tassiulas, Ioannis, Hirten, Robert , Cohen, Benjamin L., Haber, Richard S., Crane, Michael A. , Harrison, Denise , Moline, Jacqueline , Udasin, Iris , Todd, Andrew C. , Teitelbaum, Susan L. , Crowson, Cynthia, Sloan, Nancy L , Davies, Terry F. , Simpson, David Martin , Luft, Benjamin J.

Mayo Clinic

American Journal of Industrial Medicine | November 26, 2021 | Volume: 65 | Issue: 2 | Pages: 117-131

10.1002/ajim.23313 | PMID 34825393 Get It

AbstractBackgroundThe World Trade Center (WTC) general responder cohort (GRC) was exposed to environmental toxins possibly associated with increased risk of developing autoimmune conditions.ObjectivesTwo study designs were used to assess incidence and risks of autoimmune conditions in the GRC.MethodsThree clinically trained professionals established the status of possible GRC cases of autoimmune disorders adhering to diagnostic criteria, supplemented, as needed, by specialists’ review of consenting responders’ medical records. Nested case‐control analyses using conditional logistic regression estimated the risk associated with high WTC exposure (being in the 9/11/2001 dust cloud or ≥median days' response worked) compared with low WTC exposure (all other GRC members'). Four controls were matched to each case on age at case diagnosis (±2 years), sex, race/ethnicity, and year of program enrollment. Sex‐specific and sensitivity analyses were performed. GRC age‐ and sex‐adjusted standardized incidence ratios (SIRs) were compared with the Rochester Epidemiology Project (REP). Complete REP inpatient and outpatient medical records were reviewed by specialists. Conditions meeting standardized criteria on ≥2 visits were classified as REP confirmed cases.ResultsSix hundred and twenty‐eight responders were diagnosed with autoimmune conditions between 2002 and 2017. In the nested case‐control analyses, high WTC exposure was not associated with autoimmune domains and conditions (rheumatologic domain odds ratio [OR] = 1.03, 95% confidence interval [CI] = 0.77, 1.37; rheumatoid arthritis OR = 1.12, 95% CI = 0.70, 1.77). GRC members had lower SIR than REP. Women's risks were generally greater than men's.ConclusionsThe study found no statistically significant increased risk of autoimmune conditions with WTC exposures.
Association of ≥ 12 months of delayed surgical treatment for cervical myelopathy with worsened postoperative outcomes: a multicenter analysis of the Quality Outcomes Database
Asuzu, David T. , Yun, Jonathan , Alvi, Mohammed Ali , Chan, Andrew K. , Upadhyaya, Cheerag D., Coric, Domagoj , Potts, Eric A. , Bisson, Erica F. , Turner, Jay D. , Knightly, Jack, Fu, Kai-Ming, Foley, Kevin T. , Tumialán, Luis M. , Shaffrey, Mark E., Bydon, Mohamad , Mummaneni, Praveen V. , Park, Paul , Meyer, Scott A., Asher, Anthony L. , Gottfried, Oren N., Than, Khoi D. , Wang, Michael Y. , Buchholz, Avery L., Alvi, Mohammed Ali

Mayo Clinic

Journal of Neurosurgery: Spine | November 26, 2021 | Volume: 36 | Issue: 4 | Pages: 568-574

10.3171/2021.7.spine21590 | PMID 34740180 Get It

OBJECTIVE Degenerative cervical myelopathy (DCM) results in significant morbidity. The duration of symptoms prior to surgical intervention may be associated with postoperative surgical outcomes and functional recovery. The authors’ objective was to investigate whether delayed surgical treatment for DCM is associated with worsened postoperative outcomes. METHODS Data from 1036 patients across 14 surgical centers in the Quality Outcomes Database were analyzed. Baseline demographic characteristics and findings of preoperative and postoperative symptom evaluations, including duration of symptoms, were assessed. Postoperative functional outcomes were measured using the Neck Disability Index (NDI) and modified Japanese Orthopaedic Association (mJOA) scale. Symptom duration was classified as either less than 12 months or 12 months or greater. Univariable and multivariable regression were used to evaluate for the associations between symptom duration and postoperative outcomes. RESULTS In this study, 513 patients (49.5%) presented with symptom duration < 12 months, and 523 (50.5%) had symptoms for 12 months or longer. Patients with longer symptom duration had higher BMI and higher prevalence of anxiety and diabetes (all p < 0.05). Symptom duration ≥ 12 months was associated with higher average baseline NDI score (41 vs 36, p < 0.01). However, improvements in NDI scores from baseline were not significantly different between groups at 3 months (p = 0.77) or 12 months (p = 0.51). Likewise, the authors found no significant differences between groups in changes in mJOA scores from baseline to 3 months or 12 months (both p > 0.05). CONCLUSIONS Surgical intervention resulted in improved mJOA and NDI scores at 3 months, and this improvement was sustained in both patients with short and longer initial symptom duration. Patients with DCM can still undergo successful surgical management despite delayed presentation.
Survivorship, Version 1.2021
Denlinger, Crystal S. , Sanft, Tara , Ansbaugh, Shannon M., Demark‐Wahnefried, Wendy , Dickinson, Kristin , Ganz, Patricia A. , Goldman, Mindy, Henry, N. Lynn , Hill‐Kayser, Christine E. , Khakpour, Nazanin , Koura, Divya, McDonough, Allison L. , Melisko, Michelle , Mooney, Kathi , Moryl, Natalie , Moslehi, Javid J. , O’Connor, Tracey L. , Overholser, Linda , Patel, Chirayu G. , Peterson, Lindsay L. , Rodriguez, Maria Alma , Ruddy, Kathryn J. , Schapira, Lidia , Shockney, Lillie D. , Syrjala, Karen L. , Zee, Phyllis C. , McMillian, Nicole R., Freedman-Cass, Deborah A., Broderick, Gregory, Henry, N Lynn , Demark-Wahnefried, Wendy , Tevaarwerk, Amyé , Armenian, Saro H. , Baker, Kevin Scott , Broderick, Gregory A. , Day, Andrew T. , Friedman, Debra L. , Hudson, Melissa M. , Moore, Halle C. F. , Paskett, Electra D. , Pirl, William F. , Smith, Sophia K.

Mayo Clinic

Journal of the National Comprehensive Cancer Network | November 24, 2021 | Volume: 19 | Issue: 6 | Pages: 676-685

10.6004/jnccn.2021.0028 | PMID 34214969 Get It

The NCCN Guidelines for Survivorship are intended to help healthcare professionals working with cancer survivors to ensure that each survivor’s complex and varied needs are addressed. The Guidelines provide screening, evaluation, and treatment recommendations for consequences of adult-onset cancer and its treatment; recommendations to help promote healthful lifestyle behaviors, weight management, and immunizations in survivors; and a framework for care coordination. This article summarizes the recommendations regarding employment and return to work for cancer survivors that were added in the 2021 version of the NCCN Guidelines.